Some of the content on this website requires JavaScript to be enabled in your web browser to function as intended. While the website is still usable without JavaScript, it should be enabled to enjoy the full interactive experience.

Skip to Main Navigation. Each navigation link will open a list of sub navigation links.

Skip to Main Content

Wyoming Drug Utilization Review (WY-DUR)|School of Pharmacy | College of Health Sciences

Contact Us

Wyoming Drug Utilization Review (WY-DUR)
Dept. 3375
1000 E. University Ave.
Laramie, WY 82070
Phone: 307-766-6750
Fax: 307-766-2953


Preferred Drug List (PDL)

The Wyoming Medicaid Preferred Drug List (PDL) including step utilization for anti-depressant medications and prior authorization information is available at the Wyoming EqualityCare Pharmacy Provider website. To view the current PDL, please visit 

Public Comment at Meetings

 A new policy for public comment at meetings is effective December 1, 2012. 

PhRMA Guidelines and PhRMA Comment Request Form (updated December 3, 2012)

Public Guidelines and Public Comment Request Form (updated December 3, 2012)

Proposed Criteria

The following prior authorization criteria were approved at the May 8, 2014 P & T Committee meeting.

All Hepatitis C agents will require prior authorization with the following information collected:

  • Pre-screening for risky behaviors
  • Treatment history
  • Extent of liver fibrosis (Metavir score)
  • Genotype


Those with Metavir scores of F0, F1, and F2 will be sent for further review as directed by the Department of Health.  Use of Sovaldi and Olysio in combination will require additional review by Department of Health. 

Naltrexone will be limited to those with a diagnosis of alcohol or opioid dependence.   

Psychotropics in children aged 5 and under will require prior authorization with the exception of ADHD medications which are allowed down to age 3.  Requests may be sent for review by Seattle Children’s as deemed appropriate by the Department of Health.

 Prior authorization will be required for Adasuve and Zohydro ER. 

Hetlioz will be limited to its FDA approved indication. 

There was no evidence of a significant difference in safety and efficacy for Velphoro, Anoro Ellipto or Orenitram.  The Department of Health will review cost information and determine placement on the preferred drug list in their respective classes. 

Comments may be sent by email to or by mail to: Wyoming Drug Utilization Review Board, Dept. 3375, 1000 E. University Avenue, Laramie, WY   82071.   Comments should be received prior to June 30, 2014.

Board Meetings 

Agenda August 14, 2014 (revised 8/12/2014)

Minutes May 8, 2014

2014 Meetings

Wednesday, February 12; Thursday, May 8; Thursday, August 14; Thursday, November 13

All meetings are at 10 am at Laramie County Community College. Please see agenda for room location.

Share This Page:

Footer Navigation

University of Wyoming Medallion
1000 E. University Ave. Laramie, WY 82071 // UW Operators (307) 766-1121 // Contact Us // Download Adobe Reader